Abstract #286: Linagliptin (LINA) as Add-On to Empagliflozin (EMPA) and Metformin (MET) in Patients with Type 2 Diabetes Mellitus (T2DM): Two 24-Week Randomized, Doubleblind, Double-Dummy, Parallel-Group Trials – Study Design

Francisco Tinahones,Baptist Gallwitz,Matias Nordaby,Sophia Götz None,Mario Maldonado-Lutomirsky

doi:10.1016/s1530-891x(20)44994-8

Abstract #286: Linagliptin (LINA) as Add-On to Empagliflozin (EMPA) and Metformin (MET) in Patients with Type 2 Diabetes Mellitus (T2DM): Two 24-Week Randomized, Doubleblind, Double-Dummy, Parallel-Group Trials – Study Design

Francisco Tinahones, Baptist Gallwitz + Show 3 more

https://doi.org/10.1016/s1530-891x(20)44994-8

Copy DOI

Journal: Endocrine Practice

Publication Date: May 1, 2016

#Parallel-group Trials #Type 2 Diabetes Mellitus + Show 5 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Abstract #286: Linagliptin (LINA) as Add-On to Empagliflozin (EMPA) and Metformin (MET) in Patients with Type 2 Diabetes Mellitus (T2DM): Two 24-Week Randomized, Doubleblind, Double-Dummy, Parallel-Group Trials – Study Design

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Endocrine Practice

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.